Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S1: Expression of CLDN6 by transcript in the GTEX dataset of normal tissue samples.</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Martina S.J. McDermott (15206951) (author)
Бусад зохиолчид:	Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
-н: Santiago Duro-Sánchez (14959182)
Хэвлэсэн: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
-н: Kristoffer Staal Rohrberg (15009138)
Хэвлэсэн: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
-н: Sheheryar Kabraji (15050565)
Хэвлэсэн: (2025)

Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
-н: Yueren Fan (22687577)
Хэвлэсэн: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
-н: Niklas Klümper (15048887)
Хэвлэсэн: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
-н: Niklas Klümper (15048887)
Хэвлэсэн: (2025)

Image 3_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.jpeg
-н: Xi Chen (35903)
Хэвлэсэн: (2025)

Table 2_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.docx
-н: Xi Chen (35903)
Хэвлэсэн: (2025)

Table 1_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.xlsx
-н: Xi Chen (35903)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ldk63ureg1hfg2kc5i1duhilbk